pyrazines has been researched along with dactolisib in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Baumann, P; Mandl-Weber, S; Oduncu, F; Schmidmaier, R | 1 |
| Bhende, PM; Damania, B; Dittmer, DP; Lim, MS; Park, SI | 1 |
| Jang, WS; Kang, HJ; Kim, A; Lee, JE; Lee, SJ; Lee, SS; Park, S | 1 |
3 other study(ies) available for pyrazines and dactolisib
| Article | Year |
|---|---|
The novel orally bioavailable inhibitor of phosphoinositol-3-kinase and mammalian target of rapamycin, NVP-BEZ235, inhibits growth and proliferation in multiple myeloma.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Doxorubicin; Drug Synergism; G1 Phase; Humans; Imidazoles; Melphalan; Multiple Myeloma; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phosphoproteins; Phosphorylation; Protein Kinases; Proto-Oncogene Proteins c-akt; Pyrazines; Quinolines; Recombinant Proteins; Ribosomal Protein S6 Kinases, 70-kDa; TOR Serine-Threonine Kinases | 2009 |
The dual PI3K/mTOR inhibitor, NVP-BEZ235, is efficacious against follicular lymphoma.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Cell Proliferation; Female; Forkhead Transcription Factors; Humans; Imidazoles; Intracellular Signaling Peptides and Proteins; Lymphoma, Follicular; Mice; Mice, Nude; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Pyrazines; Quinolines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; TOR Serine-Threonine Kinases; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2010 |
The dual PI3K and mTOR inhibitor NVP-BEZ235 exhibits anti-proliferative activity and overcomes bortezomib resistance in mantle cell lymphoma cells.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Cell Survival; Down-Regulation; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Activation; Humans; Imidazoles; Lymphoma, Mantle-Cell; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Pyrazines; Quinolines; TOR Serine-Threonine Kinases | 2012 |